May 10, 2018 - Halozyme Therapeutics, Inc. (NASDAQ:HALO) has filed a financial statement reporting Net Cash Provided By Used In Investing Activities Continuing Operations of $-35,900,000 USD. Previously, on May 09, 2017, Halozyme Therapeutics, Inc. reported Net Cash Provided By Used In Investing Activities Continuing Operations of $4,265,000 USD. This represents a change of -941.74% in Net Cash Provided By Used In Investing Activities Continuing Operations.
Related News Stories
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)
Good day, ladies and gentlemen and welcome to the Halozyme Investor Call. We now have all of have speakers in conference. Please be aware that your line is in listen-only mode. At the conclusion on today’s presentation, we will open the floor for questions, [Operator Instructions]. (4-0)
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) posted second-quarter 2018 adjusted earnings of $2.07 per share, which came in higher than the year-ago earnings of $1.56 by 32.7%. Earnings also beat the Zacks Consensus Estimate of $1.69. Strong product revenues drove the bottom line in the quarter. (1-0)
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (4-3)
Good afternoon and welcome to the Halozyme Therapeutics First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this call is being recorded. (52-0)